SCHEMBL3067368

SCHEMBL3067368

CC(C)N1CC(c2ccc(N3CCOCC3)cc2)=CC=C1C1CCNCC1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.35
MAPT P10636 2/20 0.35
GAA P10253 1/20 0.35
ALOX12 P18054 1/20 0.35
CHRM2 P08172 1/20 0.35
CHRM4 P08173 1/20 0.35
CHRM5 P08912 1/20 0.35
CHRM1 P11229 1/20 0.35
CHRM3 P20309 1/20 0.35
MELK Q14680 1/20 0.34
PDE3B Q13370 2/20 0.34
PDE3A Q14432 2/20 0.34
KDM5B Q9UGL1 1/20 0.34
KDM4E B2RXH2 1/20 0.33
MEN1 O00255 1/20 0.33
USP2 O75604 1/20 0.33
TP53 P04637 1/20 0.33
ALOX15 P16050 1/20 0.33
MAPK1 P28482 1/20 0.33
HTT P42858 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3454830 0.76 GPR119 (0.46) TGFBR1
SCHEMBL3455672 0.73 LRRK2 (0.39) ALDH1A1MAPTCHRM2CHRM4CHRM5
SCHEMBL19139501 0.69 SIGMAR1 (0.48) ALDH1A1MAPTKDM4EMEN1USP2
SCHEMBL3464719 0.67 MAPT (0.38) ALDH1A1MAPTGAAALOX12CHRM2
SCHEMBL3065789 0.65 JAK2 (0.48) MAPTGAAMELKKDM4ELRRK2
SCHEMBL10162461 0.64 HTR3A (0.53) ALDH1A1MAPTKDM4EMEN1USP2
SCHEMBL3067369 0.64 MAPT (0.34) ALDH1A1MAPTGAAALOX12CHRM2
SCHEMBL7082120 0.64 ADRB1 (0.63) ALDH1A1MAPTKDM4EMEN1USP2
SCHEMBL23410248 0.63 HRH1 (0.53) ALDH1A1MAPTMEN1HTTKMT2A
Bromide SCHEMBL6539744 0.62 ADRB1 (0.61) ALDH1A1MAPTKDM4EMEN1USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100267721-A1 Heterocyclic H3 Antagonists HIGH POINT PHARMACEUTICALS LLC (US) 2010-10-21 US claimed
EP-2166850-A1 NEW HETEOCYCLIC H3 ANTAGONISTS High Point Pharmaceuticals, LLC (US) 2010-03-31 EP disclosed
WO-2008154126-A1 NEW HETEOCYCLIC H3 ANTAGONISTS HIGH POINT PHARMACEUTICALS, LLC (US) 2008-12-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100267721-A1 Heterocyclic H3 Antagonists HRH3, HRH4, HRH2 ALDH1A1 3867/4885MAPT 4831/4885GAA 4835/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.